Generic Medicine Info
Indications and Dosage
Neonatal respiratory distress syndrome
Child: Premature neonates <29 weeks gestational age and newborns ≤72 hours of age: 105 mg phospholipids/kg (3 mL/kg) given as soon as possible, preferably within 30 minutes of birth (as prophylaxis), or as soon as diagnosis is confirmed (as treatment). May repeat dose every 12 hours for a total of up to 3 doses if with continued distress.
Special Precautions
Infant at risk of intraventricular haemorrhage and periventricular leukomalacia. Not indicated as a substitute for neonatal intensive care. Children.
Adverse Reactions
Significant: Cyanosis, airway obstruction, bradycardia, reflux into the endotracheal tube, reintubation, hypoventilation.
Monitoring Parameters
Monitor heart rate and transcutaneous oxygen saturation during administration. Perform frequent arterial blood gas sampling after initial dose.
Description: Calfactant, an endogenous lung surfactant, from calf lung extract of phospholipid, neutral lipids and hydrophobic surfactant-associated proteins B and C. It restores surface activity to the lungs by modifying the alveolar surface tension thus, stabilising the alveoli. It adsorbs rapidly to the surface of the air, liquid interface and modifies surface tension similarly to natural lung surfactant.
Onset: 24-48 hours.
Store upright, between 2-8°C. Do not freeze. Do not shake. Protect from light.
MIMS Class
Other Drugs Acting on the Respiratory System
Anon. Calfactant. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 09/05/2019.

Buckingham R (ed). Pulmonary Surfactants. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 09/05/2019.

Infasurf (Ony Biotech Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 09/05/2019.

Disclaimer: This information is independently developed by MIMS based on Calfactant from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in